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Background: There have been major changes in the management of anemia in US hemodialysis patients in recent
years. We sought to determine the influence of clinical trial results, safety regulations, and changes in
reimbursement policy on practice.
Methods: We examined indicators of anemia management among incident and prevalent hemodialysis patients
from a medium-sized dialysis provider over three time periods: (1) 2004 to 2006 (2) 2007 to 2009, and (3) 2010.
Trends across the three time periods were compared using generalized estimating equations.
Results: Prior to 2007, the median proportion of patients with monthly hemoglobin >12 g/dL for patients on
dialysis 0 to 3, 4 to 6 and 7 to 18 months, respectively, was 42%, 55% and 46% declined to 41%, 54%, and 40% after
2007, and declined more sharply in 2010 to 34%, 41%, and 30%. Median weekly Epoeitin alpha doses over the same
periods were 18,000, 12,400, and 9,100 units before 2007; remained relatively unchanged from 2007 to 2009; and
decreased sharply in the patients 3–6 and 6–18 months on dialysis to 10,200 and 7,800 units, respectively in 2010.
Iron doses, serum ferritin, and transferrin saturation levels increased over time with more pronounced increases in
2010.
Conclusion: Modest changes in anemia management occurred between 2007 and 2009, followed by more
dramatic changes in 2010. Studies are needed to examine the effects of declining erythropoietin use and
hemoglobin levels and increasing intravenous iron use on quality of life, transplantation rates, infection rates and
survival.
Keywords: Anemia, Erythropoietin stimulating agents, HemodialysisBackground
Efforts to identify an anemia management strategy that
optimizes clinical outcomes and quality of life among
hemodialysis (HD) patients have received substantial atten-
tion in recent years [1,2]. Until recently, ESA use in patients
with chronic kidney disease (CKD) had been steadily in-
creasing [3]. Average doses of erythropoiesis stimulating
agents (ESAs) in 2006 were threefold higher than they were
in 1991 and ESAs accounted for $2 billion of Medicare
expenditures [3]. Such changes occurred despite early* Correspondence: dmiskulin@tuftsmedicalcenter.org
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reproduction in any medium, provided the orexperiences indicating that there was an increased risk of
thromboembolic events, worsened hypertension, and sei-
zures with treatment with ESAs. In 2006, a major trial
found an increased risk of cardiovascular events and death
of treating CKD patients to higher versus lower Hb targets
[4]. Two other trials, one involving HD patients and pub-
lished in 1998 [5], and the other, involving CKD patients
and also published in late 2006 [6], reported no benefit with
treating to higher Hb values.
In response to these findings and studies showing an in-
crease in cancer deaths in oncology patients, the U.S. Food
and Drug Administration (FDA) issued a black box warning
on ESA labels in March 2007, recommending ESAs be used
at the lowest possible dose to avoid transfusion [7]. At this
same time, a short term, randomized trial found thatl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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serum ferritin 500–1000 and TSat <25% led to a significant
increase in Hb and decline in EPO dose [8]. In late 2009, a
fourth major of targeting a high vs. lower Hb was pub-
lished, and showed an increase in stroke (a secondary end-
point) with targeting higher Hb values in CKD patients [9].
The FDA issued new safety regulations, requiring that ESAs
be prescribed under a risk evaluation and mitigation pro-
gram [10].
Recent changes to reimbursement for dialysis care
may have also influenced practice. Prior to January 1,
2011, the Centers for Medicare and Medicaid Services
(CMS) reimbursed dialysis facilities for ESAs at the aver-
age wholesale price plus 6 percent [11]. In August 2010,
CMS announced the final rules for the ESRD Prospect-
ive Payment System (ESRD PPS) or bundled payment
system, under which injectable medications administered
in HD units, including ESAs, each be reimbursed at a
fixed rate, regardless of dose, beginning January 1, 2011
[11].
We sought to determine the potential influence of clinical
trial results and changes in safety regulations with changes
in reimbursement policies on anemia management prac-
tices in a representative U.S. HD population.
Methods
Study population
We performed a series of cross-sectional analyses to
characterize patterns of anemia management during the
first 18 months of HD from 2004 to 2010 in Dialysis
Clinic, Inc (DCI), a medium-sized not-for-profit US dia-
lysis provider with approximately 200 dialysis units
across the US. We included patients who survived at
least three months from the time of dialysis initiation,
had at least one HD treatment and at least one
hemoglobin (Hb) measurement. We excluded patients
who received peritoneal dialysis or home HD between
2004 and 2010.
Data
We obtained data from DCI’s electronic medical infor-
mation system. Laboratory measures for Hb, serum fer-
ritin, iron and transferrin had been processed at the DCI
Central Laboratory (Nashville, TN), which is certified by
the Clinical Laboratory Improvement Amendments. We
calculated TSat using the formula: (TSat = iron/transfer-
rin*70.9). If more than one value of a laboratory param-
eter (e.g., Hb) existed in a month, we took the median of
all values. The cumulative IV iron dose per month was
calculated as the sum of iron dextran, iron sucrose or
iron gluconate administered each month. If there was no
record of IV iron administered for a treatment, the dose
was zero. The median weekly EPO dose per month was
calculated as the cumulative weekly EPO dose first, andthen we took the median of the weekly doses over the
month. The study was conducted in accordance with the
Declaration of Helsinki and was approved by the
Johns Hopkins Medicine Institutional Review Board
(Baltimore, Maryland).
Statistical analysis
We stratified analyses according to patients’ time on HD
(i.e. 0–3, 4–6 and 7–18 months after starting HD) to ac-
count for differences in ESA and iron dosing at dialysis
initiation when patients often require more ESA and iron
than later on.
We examined trends in anemia management over three
time periods: 1) 2004–2006; 2) 2007–2009, which follows
the publication of a major trial showing harm with target-
ing a higher Hb in CKD patients and another showing no
benefit [4,6] as well as the FDA’s issuance of a black box
warning on the EPO label advising against targeting higher
Hb levels [7]; and 3) 2010, which follows publication of
another trial showing increase in strokes with treating CKD
patients to a higher Hb target [9] and release of the Final
Rule for a bundled CMS payment system [11] to be enacted
January 1, 2011. To examine whether the changes in
anemia management between time periods were statistically
significant, we modeled the anemia parameters for each
individual using generalized estimating equations (GEE)
models which account for ‘within subject’ as well as ‘be-
tween clinic’ correlations. Hb >12 g/dL and Hb <10 g/dL
were modeled as binary outcomes, and ferritin, TSat, and
EPO dose were modeled as continuous outcomes. To
examine the trends in IV iron doses overtime, we used
two-stage GEE models as a substantial proportion of pa-
tients did not receive IV iron in a given month. In the first
stage, we modeled the binary outcome of “any” versus
“zero” doses; and for the second stage we modeled iron
dose as a continuous variable, among those receiving iron.
We created linear spline terms with knots at January 2007
and January 2010 to test for differences in the initial values
(i.e. intercepts) and rates of change (i.e. slopes) during the
three time periods (2004–2006, 2007–2009 and 2010). We
adjusted all models for age, race/ethnicity, gender, and
diabetes status. Analyses were conducted using SAS 9.2
(Cary, NC).
Results
Study population
We observed anemia management practices among
12,281, 13,288, and 6,142 patients who dialyzed between
2004–2006, 2007–2009 and 2010, respectively, at dialysis
units within Dialysis Clinic Inc, (DCI). Patient character-
istics across the three time periods were similar to those
of patients initiating dialysis across the US, with the
exception of a higher proportion of African American
(36% vs. 28%) and a lower proportion of Hispanics (6%
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was African American or Hispanic, 45–64 years old, and
with ‘other’ causes of ESRD, increased over the three
time periods (Table 1).
Unadjusted trends in anemia management
Per Table 2 we find that the percent of patients with Hb
>12 g/dL decreased between 2004–2006 and 2007–2009
and fell even more sharply in 2010. This was accompanied
by an increase in Hb <10 g/dL and a parallel decrease in
the percent of patients with a Hb >12 g/dL. Median Epoe-
tin Alfa (EPO) doses were similar over 2004 to 2006 and
2007–2009 but decreased dramatically in 2010. The per-
centage of patients receiving monthly intravenous (IV)
iron also was lower in 2010, compared to the periods be-
fore 2007. However, among patients who received IV iron,
the median doses were higher between 2007 to 2009 and
in 2010 compared to before 2007. Median values of serum
ferritin, and transferrin saturation (TSat) also increased
across periods.
Time trends in anemia management
Hemoglobin
Results are described separately by subgroups defined by the
time since starting dialysis (0–3, 4–6, 7–18 months), as
trends were different depending on dialysis vintage. BetweenTable 1 Patient characteristics, by time period
Total no. (N)
Age at first dialysis treatment at DCI, mean (SD)
Age category at first dialysis treatment at DCI, N (%) 18–44
45–64
≥65
Sex, N (%) Male
Female
Race, N (%) African American
White
Other2
Unknown
Ethnicity, N (%) Hispanic
Non-Hispanic
Unknown
Primary cause of ESRD, N (%) Diabetes
Hypertension
Glomerulonephriti
Other
Unknown
1Chi-square test.
2American Indian, Asian or Pacific Islander.January 2004 and December 2006, the percentage of pa-
tients with Hb >12 g/dL increased among patients on dialy-
sis for 0–3, 4–6, and 7–18 months, from 33 to 41%, 45 to
56%, 45 to 51%, respectively, but declined between 2007–
2009 and by the end of 2009, were at values seen back in
2004. The proportion with Hb >12 g/dL fell more sharply in
2010 except in new patients 0–3 months on dialysis where
there was an increase in Hb > 12 g/dL (Figure 1a).
The changes in the frequency of Hb <10 g/dL
(Figure 1b) were the opposite of the trends described
above for Hb >12 g/dL, with a decrease in Hb <10 g/dL be-
tween 2004–2006, an increase between 2007–2009 and fur-
ther increases in 2010, such that by December, 2010, 17%
of patients who had been receiving dialysis for 0–3 months,
5% of patients dialyzed for 4 to 6, months and 7% of
patients dialyzed for 7–18 months had a Hb <10 g/dL.
Changes in the frequency of Hb > 12 g/dL and Hb <10 g/dL
across the 3 periods were statistically significant for all com-
parisons except for the change in Hb <10 g/dL between
2007–2009 and 2010 in the subgroup of patients who had
been dialyzing for 4–6 months.
Epoetin alfa utilization
Weekly EPO dose was essentially unchanged between 2004
and 2006 (Figure 1c). Between 2007–2009, EPO dose in-
creased from 19,133 to 21,805 units among patientsYears
2004–2006 2007–2009 2010 p-value1
12,281 13,288 6,142 <0.01
62.2 (15.4) 62.0 (15.3) 61.9 (15.3) 0.35
1,773 (14.4) 1,882 (14.2) 864 (14.1) <0.01
4,736 (38.6) 5,374 (40.4) 2,546 (41.5)
5,772 (47.0) 6,032 (45.4) 2,732 (44.5)
6,854 (55.8) 7,439 (56.0) 3,452 (56.2) 0.88
5,427 (44.2) 5,849 (44.0) 2,690 (43.8)
4,357 (35.5) 4,766 (35.9) 2,264 (36.9) <0.01
7,050 (57.4) 7,550 (56.8) 3,425 (55.8)
802 (6.5) 867 (6.5) 377 (6.1)
72 (0.6) 105 (0.8) 76 (1.2)
682 (5.6) 828 (6.2) 421 (6.9) <0.01
11,535 (93.9) 12,308 (92.6) 5,598 (91.1)
64 (0.5) 152 (1.1) 123 (2.0)
5,529 (45.0) 6,001 (45.2) 2,771 (45.1) 0.03
3,511 (28.6) 3,847 (29.0) 1,758(28.6)
s 1,152 (9.4) 1,121 (8.4) 526 (8.6)
2,045 (16.7) 2,284 (17.2) 1,078 (17.6)
44 (0.4) 35 (0.3) 9 (0.2)
Table 2 Anemia management parameters by time on dialysis and dialysis incidence year
Time on
dialysis
Incidence year
2004–2006 2007–2009 2010
Hemoglobin (g/dl), Median (Q25, Q75) 0–3 month 11.7 (10.4, 12.9) 11.6 (10.3, 12.8) 11.4 (10.0, 12.5)
3–6 month 12.3 (11.3, 13.2) 12.3 (11.4, 13.0) 12.0 (11.2, 12.7)
6–18 month 12.1 (11.2, 12.9) 11.9 (11.1, 12.7) 11.8 (10.9, 12.5)
Percent with Hemoglobin <10 (monthly), Median (Q25, Q75) 0–3 month 12.8 (8.2, 30.4) 13.3 (7.6, 34.0) 17.1 (9.3, 42.8)
3–6 month 7.0 (6.6, 7.1) 6.7 (6.5, 7.4) 7.7 (6.6, 8.0)
6–18 month 6.2 (6.0, 6.5) 6.8 (6.5, 6.9) 8.9 (8.3, 9.3)
Percent with Hemoglobin > 12 (monthly), Median (Q25, Q75) 0–3 month 42.0 (17.8, 57.1) 40.6 (14.5, 57.4) 33.6 (9.08, 49.5)
3–6 month 54.9 (50.5, 58.7) 54.2 (49.8, 58.2) 41.2 (35.8, 48.4)
6–18 month 45.9 (44.6, 49.7) 39.9 (36.9, 46.1) 29.5 (25.7, 35.9)
Weekly ESA doses (Unit), Median (Q25, Q75) 0–3 month 18000 (9000, 30000) 20000 (9000, 30600) 18000 (8000, 30000)
3–6 month 12400 (4800, 24000) 13500 (4800, 25200) 10200 (2600, 21000)
6–18 month 9100 (3900, 19500) 9600 (3900, 20100) 7800 (2400, 16800)
Percent of patients receiving monthly IV iron, Median (Q25, Q75) 0–3 month 71.1 (62.5,72.5) 77.8 (67.9,78.5) 76.0 (72.6,77.4)
3–6 month 71.0 (69.7,72.0) 74.5 (73.6,76.2) 70.3 (68.9,73.6)
6–18 month 65.7 (64.5,68.2) 67.4 (65.9,70.4) 60.6 (58.1,62.2)
Monthly iron doses (mg) for those who had received iron, Median (Q25, Q75) 0–3 month 400 (200,800) 475 (200,800) 500 (300,850)
3–6 month 300 (200,500) 300 (200,500) 400 (200,600)
6–18 month 200 (125,400) 225 (125,400) 300 (200,500)
TSat(%), Median (Q25, Q75) 0–3 month 18.4 (13.7, 24.8) 18.3 (13.9, 24.5) 21.5 (16.1, 28.4)
3–6 month 22.6 (17.0, 30.3) 22.6 (17.2, 30.0) 24.4 (19.1, 32.8)
6–18 month 23.6 (18.3, 30.5) 23.6 (18.4, 30.5) 25.6 (20.3, 33.3)
Ferritin (ng/ml), Median (Q25, Q75) 0–3 month 284 (136, 533) 312 (157, 566) 354 (179, 624)
3–6 month 447 (243, 687) 499 (287, 744) 600 (360, 858)
6–18 month 592 (376, 796) 654 (436, 893) 707 (474, 996)
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Figure 1 Multivariable adjusted Hb and EPO doses 2004-2010 among patients 0–3, 4–6 and 7–18 months on dialysis. Panel
(a) Percentages of patients with Hb < 10 g/dL; Panel (b) Percentages of patients with Hb > 12 g/dL; Panel (c) Weekly EPO doses. Vales are
based on white males greater than 65 years old with diabetes as the cause of ESRD. The slopes represent monthly rates of change during each
of the three time periods (2004–2006, 2007–2009 and 2010). The “*” indicate that the slope is significantly different from 0. The grey dotted lines
are 95% confidence intervals for the adjusted values. The difference in slopes for Hb < 10, Hb >10 g/dL and EPO dose within each ‘time on
dialysis’ subgroup between 2004–2006 and 2007–2009 and between 2007–2009 and 2010 were statistically significant except for Hemoglobin
< 10 g/dL in the 4–6 month patient subgroup between 2007–2009 and 2010.
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patients dialyzing 4–6 months and 14,931 to 17,091 units
among patients dialyzing 7–18 months. Doses declined
sharply in 2010 to 15,302, 12,211 and 10,951 units in these
same groups, respectively, which represents a 30%, 35%
and 36% decline. The rates of change in EPO dose across
the three time periods were statistically significant in each
subgroup.Figure 2 Multivariable adjusted iron doses and markers of iron stores
Panel (a) Monthly iron dose (mg); Panel (b) Serum ferritin (ng/ml); Panel
old with diabetes as the cause of ESRD. The slopes represent monthly rates
and 2010). The “*” indicate that the slope is significantly different from 0. Th
values. The difference in slopes between 2004–2006 and 2007–2009 and be
‘time on dialysis’ subgroup for each of the parameters except for the comp
2007–2009 and 2010, and ferritin in the 0–3 month subgroup between 200Intravenous iron therapy
Between January 2004 and December 2006, the percent-
age of patients receiving monthly IV iron, increased from
70% to 74%, 70% to 74%, and 69% to 71% among patients
who had been treated with HD for 0–3, 4–6 and 7–18
months, respectively. There were small increases in
each of the three subgroups between 2007–2009 and a
small decline in 2010.2004-2010 among patients 0–3, 4–6, and 7–18 months on dialysis.
(c) TSat (%). Values are based on white males greater than 65 years
of change for each of the three time periods (2004–2006, 2007–2009
e grey dotted lines are 95% confidence intervals for the predicted
tween 2007–2009 and 2010 are statistically significant within each
arisons of monthly iron dose in the 0–3 month subgroup between
4–2006 and 2007–2009.
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was no clinically meaningful change in monthly IV
iron doses between 2004 to 2006 or between 2007 to
2009. Between January 2010 and December 2010, the
adjusted monthly IV iron dose increased from 532 to
547, 394 to 446 and 325 to 394 mg respectively,
among patients 0–3, 4–6 and 7–18 months on dialy-
sis. The increase in iron dose before and after 2010
was statistically significant in the prevalent subgroups
(dialyzing 4–6 and 7–18 months).
Transferrin saturation and ferritin
There was no significant change in multivariable ad-
justed TSat values between 2004–2006 and 2007–2009
for any subgroup by time on dialysis (Figure 2b). Be-
tween January and December 2010, there were statisti-
cally significant increases in TSat values from 20% to
26%, 24% to 25% and 24% to 28% in patients 0–3, 4–6,
and 7–18 months on dialysis.
Serum ferritin steadily increased from 2004 through
the end of 2010 in each of the subgroups (Figure 2c),
with changes of 370 to 541 mg, 470 to 707, and 546 812
ng/ml, in patients who had received dialysis for 0–3, 4–6
and 7–18 months, respectively. The rates of change in
TSat and serum ferritin levels across the 3 time periods
were statistically significant for all subgroups except for
ferritin in the incident patients (dialyzing 0–3 months)
between 2004-2006 and 2007- 2009.
Discussion
Our results suggest that the 2006 publication of a clin-
ical trial demonstrating harm with targeting higher Hb
levels [4] and the FDA’s issuance of a black box warning
on the epoeitin label [7] led to relatively modest changes
in anemia management as compared with the much
sharper declines in Hb and EPO doses that were seen in
2010 after publication of another trial showing harm
with higher Hb values [9] and CMS’s release of the final
rule for a revised payment system [11]. Over the course
of 2010, there was a nearly 30% decline in the propor-
tion of patients with Hb greater than12 g/dL and a more
than 30% decline in median EPO doses.
Our observations are consistent with the USRDS Annual
Data Report [12], which showed more dramatic reductions
in EPO doses and in the proportion of patients with Hb
levels greater than 12 g/dL in 2010 than in earlier years. It
is impossible to tell whether these changes in anemia man-
agement practices were influenced more by the publication
of a second major trial showing harm with targeting a
higher Hb value or preparations for bundled payment pol-
icies for dialysis care, as the two occurred at the same time.
Practice may not have changed following publication of a
major trial showing harm with targeting high Hb in late
2006 because it was conducted in CKD patients andnephrologists may have considered that these results did
not apply to HD patients. However, if this was the explan-
ation, the TREAT trial, published in late 2009, should also
not have led to the large changes in practice seen in 2010,
as it was also conducted in CKD patients. These findings
may suggest that US dialysis units may be much more sen-
sitive to changes in payment policies than research find-
ings and FDA regulations. We speculate that the changes
in payment policies likely reinforced and incentivized clini-
cians’ further modifications to their practice patterns to
achieve still lower hemoglobin levels through 2010, pri-
marily through more sparing use of EPO. The immediate
and dramatic declines in EPO use observed in our study
reflect the high costs of EPO, as well as dialysis organiza-
tions’ motivation and ability to minimize use of costly
ESAs while achieving appropriate anemia management
goals through centralized prescribing protocols [13].
Only a small proportion of patients had Hb values less
than 10 mg/dl in 2010, though these data predate changes
in the CMS Quality Incentive Program (QIP), under which
the penalty for Hb values falling below 10 g/dL was re-
moved in 2013 [14]. Per data from the US Dialysis Out-
comes and Practice Patterns Study (DOPPS) EPO doses
have continued to decline through 2011, as has the preva-
lence of Hb less than 10 g/dL [15]. An increase in blood
transfusions, longer transplant waiting times as a result of
sensitization, as well as declines in physical functioning,
cognition and health-related quality of life are potential
consequences of a decline in Hb values in the HD popula-
tion. It is clear that some patients would be willing to
accept higher risks of harms (e.g., stroke, myocardial infarc-
tion or death) in return for improved cognitive and physical
functioning. To individualize anemia management, we need
sensitive measures of cognition, physical health and quality
of life as well as open discussion among physicians and
their patients about their values and preferences. Attention
toward patients’ preferences regarding the potential trade-
offs associated with anemia management strategies may be
particularly pertinent in light of the downward shift in dis-
tribution of Hb levels that we observed and we anticipate
will continue, with the removal of the QIP penalty for Hb
less than 10 g/dL in 2013 [14].
Our study is strengthened by its examination of sev-
eral years of anemia management in a large, representa-
tive US dialysis population. We are unaware of other
studies explicitly exploring the influence of secular
events on trends in anemia management. Our study also
has limitations. DCI is a not-for-profit dialysis provider,
which may respond differently to secular factors than
for-profit dialysis providers. We suspect this is not the
case, however, as the general trends reported in this
study are similar to those reported by the USRDS [16].
We do not examine trends in practice beyond 18 months
after starting dialysis, as at the time of data extraction,
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longed follow-up was limited. It is possible that the
trends seen here are not applicable to very prevalent
patients (greater than 18 months after starting dialysis).
Although we attempted to describe trends in anemia
management in relation to secular events, we cannot
make causal inferences, as clinical trial publications
overlapped with changes in product label regulations
and in reimbursement. Nonetheless, we believe our de-
tailed description of changes in several key indices of
anemia management in relation to the publication of
major clinical trial results, and changes in regulatory and
reimbursement policies, provide insight into numerous
potential influences that affect anemia management and
patient outcomes.
Conclusion
In conclusion, modest changes in anemia management
occurred after 2007, with more substantial changes after
2010. Both scientific evidence indicating harms with target-
ing higher Hb levels, and changes in dialysis reimbursement
policies appear to have been associated with these changes,
though more dramatic changes coincided with the latter.
Study of the effects of treating to lower Hb values, and the
use of less ESA and more IV iron, on morbidity, mortality,
transplant waiting times, and health related quality of life
are needed.
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